Triptolide has been demonstrated in ovarian cancer cell lines and animal models to reduce ovarian cancer chemoresistance by interrupting PI3K/AKT/GSK3‐β and JAK/STAT3 signaling pathways.116, 117. This evidence concerns the gene AKT1 and ovarian carcinoma.